Why Thousands Are Missing Timely Cancer Treatments: The Shocking Truth About STLD Health Plans!

The expansion of short-term limited-duration (STLD) health plans by the federal government in 2018 has sparked significant concern among healthcare experts, particularly in its impact on cancer treatment initiation for newly diagnosed patients. Originally limited to three months, the duration of these plans was extended to less than 12 months, with a renewal option allowing for a total coverage period of up to 36 months. This change, while aimed at providing more flexible options for insurance, has had unintended consequences, especially in states with minimal regulation on these plans.

A recent study published by the American Cancer Society (ACS) highlights the alarming effects of limited or nonexistent state regulations on STLD health plans. Researchers found a clear association between these lax regulations and delays in the timely initiation of treatment for patients diagnosed with female breast cancer, colorectal cancer, or non-small cell lung cancer (NSCLC). The study, led by Jingxuan Zhao, PhD, a senior scientist in health services research at ACS, underscores the risks patients face when opting for STLD plans, which are not required to cover essential health benefits mandated by the Affordable Care Act (ACA).

“STLD plans are not required to cover essential health benefits, such as cancer screenings, hospitalizations, and prescription drugs,” Dr. Zhao said. “People living in states with limited or no regulation of STLD plans may choose these plans over ACA-compliant insurance due to lower premiums, without fully understanding the limitations of this plan coverage.”

To conduct the study, researchers analyzed data from adults aged 18 to 64 years who were newly diagnosed with the aforementioned cancers from 2017 to 2019, using the National Cancer Database. They categorized patients based on the STLD policies of their states as of December 2019, identifying five distinct regulatory environments: (1) continuously prohibited; (2) prohibited after 2018; (3) continuously limited to three months; (4) less stringent regulations post-2018; and (5) no additional regulations after 2018.

The findings were striking. States that allowed STLD plans with limited restrictions saw larger declines in the percentage of cancer patients beginning treatment within 30 days of diagnosis compared to states with stringent prohibitions. The most significant drop occurred in states with no additional regulations, where nearly 8,000 patients diagnosed with female breast cancer, colorectal cancer, or NSCLC each year could face delays in treatment initiation. This number could rise substantially when considering individuals diagnosed with other cancers or those experiencing cancer recurrences.

Looking ahead, Dr. Zhao noted that while a new federal rule enacted in 2024 limits STLD plans to a maximum of three months, future administrations may alter these regulations. “It is important to understand and continue monitoring the potential adverse effects of federal and state STLD plan policies on access to cancer care and patient outcomes,” she added.

The ACS has long advocated for stringent regulations at both federal and state levels to limit access to STLD plans, underscoring the dangers these plans pose. “Research shows that having comprehensive health insurance is a major determining factor in surviving cancer,” said Lisa Lacasse, President of the American Cancer Society Cancer Action Network (ACS CAN). “STLD plans are especially dangerous because they don’t provide comprehensive coverage and can discriminate against individuals with preexisting conditions like cancer.”

Lacasse further urged Congress to pursue a bipartisan approach to extend enhanced premium tax credits, making comprehensive health insurance more affordable for millions, so that no one is left uninsured or forced into a non-comprehensive STLD plan that fails to meet the needs of cancer patients and survivors.

As the healthcare landscape continues to evolve, the implications of STLD plans raise critical questions about patient access, treatment efficacy, and overall health outcomes. The findings from this study serve as a vital reminder of the importance of regulatory oversight to protect vulnerable populations, especially those facing life-threatening illnesses.